These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25120629)

  • 1. Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.
    Hu ZJ; Ren LP; Wang C; Liu B; Song GY
    Exp Ther Med; 2014 Sep; 8(3):951-956. PubMed ID: 25120629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan.
    Chang PY; Lee CM; Hsu HC; Lin HJ; Chien KL; Chen MF; Chen CH; Lee YT; Yang CY
    Lipids Health Dis; 2012 Nov; 11():162. PubMed ID: 23173569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA polymorphisms at the apolipoprotein A1-CIII loci in Taiwanese: correlation of plasma APOCIII with triglyceride level and body mass index.
    Wu JH; Kao JT; Wen MS; Lo SK
    J Formos Med Assoc; 2000 May; 99(5):367-74. PubMed ID: 10870325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses.
    Klein RL; McHenry MB; Lok KH; Hunter SJ; Le NA; Jenkins AJ; Zheng D; Semler AJ; Brown WV; Lyons TJ; Garvey WT;
    Metabolism; 2004 Oct; 53(10):1296-304. PubMed ID: 15375785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses.
    Peacock RE; Hamsten A; Johansson J; Nilsson-Ehle P; Humphries SE
    Clin Genet; 1994 Oct; 46(4):273-82. PubMed ID: 7834891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort.
    Klein RL; McHenry MB; Lok KH; Hunter SJ; Le NA; Jenkins AJ; Zheng D; Semler A; Page G; Brown WV; Lyons TJ; Garvey WT;
    J Diabetes Complications; 2005; 19(1):18-25. PubMed ID: 15642486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease.
    Lee SJ; Moye LA; Campos H; Williams GH; Sacks FM
    Atherosclerosis; 2003 Apr; 167(2):293-302. PubMed ID: 12818412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.
    Mendivil CO; Zheng C; Furtado J; Lel J; Sacks FM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):239-45. PubMed ID: 19910636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between apolipoprotein CIII gene polymorphism and serum lipid levels in Han Chinese males.
    Su S; Tang M; Zhang M; Cheng C; Tang X
    Meta Gene; 2013 Dec; 1():58-64. PubMed ID: 25606375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.
    Ding Y; Wang Y; Zhu H; Fan J; Yu L; Liu G; Liu E
    Transgenic Res; 2011 Aug; 20(4):867-75. PubMed ID: 21120692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.
    Xiong X; Liu H; Hua L; Zhao H; Wang D; Li Y
    Lipids Health Dis; 2015 Oct; 14():127. PubMed ID: 26452348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T; Ramakrishnan R; Steiner G; Shachter NS
    J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.
    Yan H; Niimi M; Matsuhisa F; Zhou H; Kitajima S; Chen Y; Wang C; Yang X; Yao J; Yang D; Zhang J; Murakami M; Nakajima K; Wang Y; Liu E; Liang J; Chen YE; Fan J
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2095-2107. PubMed ID: 32757647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and determinants of microalbuminurea among type 2 diabetes mellitus patients, Baghdad, Iraq, 2013.
    Ali AA; Al Lami FH
    Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):348-55. PubMed ID: 26997390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia.
    Zhang T; Tang X; Mao L; Chen J; Kuang J; Guo X; Xu D; Peng D; Yu B
    Clin Biochem; 2020 May; 79():14-22. PubMed ID: 32045574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
    Lee SJ; Campos H; Moye LA; Sacks FM
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):853-8. PubMed ID: 12637336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
    Kypreos KE
    Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.
    Bevilacqua M; Guazzini B; Righini V; Barrella M; Toscano R; Chebat E
    Curr Ther Res Clin Exp; 2004 Jul; 65(4):330-44. PubMed ID: 24672088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of plasma apolipoprotein CIII, high sensitivity C-reactive protein and tumor necrosis factor-α contributes to the clinical features of coronary heart disease in Li and Han ethnic groups in China.
    Chen L; Sun M; Liu H; Ma L; Wang T; Li P; Lin M; Lin H; Chang P; Liu Y
    Lipids Health Dis; 2018 Jul; 17(1):176. PubMed ID: 30053815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.